> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-200/
- Published: 2019-06-25T12:00:00.000Z
- Updated: 2026-09-15T01:34:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144423

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**International Hospital Products**, Littleton, CO (5/29): FDA inspected the firm 3/15-19 and cited GMP violations with its Baker Jejunostomy and intestinal tubes used for bowel decompression. For example, the company’s process validation activities and results have not been adequately documented and adequately approved. It was also cited for not establishing procedures for finished device acceptance. Additionally, the company could not provide a Device Master Record for its Class II devices. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-hospital-products-inc-579332-05292019?ref=fdaweb.com).

**Rxhomeo Private Ltd.** Hyderabad, India (6/13): FDA inspected the firm in January and cited significant GMP violations for finished pharmaceuticals. For example, the firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Additionally, the firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rxhomeo-private-limited-575889-06132019?ref=fdaweb.com).

**Xi’an Livingbond Nonwoven Products**, Xian Shaanxi, China (6/10): FDA inspected the firm in January and cited significant GMP violations for finished pharmaceuticals. For example, the company failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications. The firm also failed to conduct at least one test to verify the identity of each component of a drug product. And, the company failed to establish written procedures for production and process controls. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xian-livingbond-nonwoven-products-corp-ltd-574591-06102019?ref=fdaweb.com).